Aprezo® 30 mg is an oral prescription medication containing apremilast, a selective phosphodiesterase-4 (PDE4) inhibitor used in the management of certain chronic inflammatory disorders.
Manufactured by Glenmark Pharmaceuticals, Aprezo is designed to help regulate inflammatory pathways involved in psoriasis and psoriatic arthritis. The convenient oral tablet formulation offers an alternative to injectable treatment options for eligible patients.
Active ingredient:
Dosage form:
Available pack sizes:
Apremilast works by inhibiting phosphodiesterase-4 (PDE4), an enzyme involved in the regulation of inflammatory mediators.
By modulating inflammatory signaling pathways, Aprezo may help:
Unlike many biologic therapies, Aprezo is administered orally and does not require injections.
Aprezo may be prescribed for:
Treatment should always be initiated and monitored by a qualified physician.
Convenient tablet form without injections.
Acts on important inflammatory pathways through PDE4 inhibition.
Suitable for ongoing treatment plans under medical supervision.
Addresses both skin and joint manifestations of disease.
Produced by Glenmark Pharmaceuticals under established quality standards.
Depending on individual response, treatment may help:
Individual results may vary.
Take Aprezo exactly as prescribed by your healthcare provider.
The dosage regimen should be determined by a qualified medical professional based on the patient's condition and treatment goals.
Do not alter the prescribed dose without medical advice.
Aprezo is commonly prescribed for the treatment of psoriasis and psoriatic arthritis.
Each tablet contains 30 mg of apremilast.
No. Apremilast is not a corticosteroid and does not belong to the hormonal drug class.
No. It is supplied as oral tablets.
It inhibits the PDE4 enzyme, helping regulate inflammatory responses involved in chronic inflammatory diseases.
Treatment duration is determined by a healthcare professional based on efficacy and tolerability.
Ask a question or inquire about delivery to your country